{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methylene blue
to a specific field?
Status:
Investigational
Source:
INN:monlunabant [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Exisulind (tentative trade name Aptosyn) is an antineoplastic agent, which was originally developed by Cell Pathways. This drug is an inhibitor of phosphodiesterase (PDE) isozymes: PDE5 and PDE4. Inhibition of PDE5 appears to be pharmacologically relevant, which leads to increase cGMP and activate protein kinase G at doses that induce apoptosis, whereas cyclic AMP levels were not changed. Exisulind has been in phase III clinical trials for the treatment of Non-Small Cell Lung Cancer and for the treatment of polyps in patients who have familial adenomatous polyposis (Colorectal Cancer and Small Intestine Cancer). In addition, this drug was in phase II/III for the treatment of Prostate Cancer, however, there studies have been discontinued.
Status:
Investigational
Source:
INN:levofuraltadone [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Levofuraltadone is the nitrofurane used for the treatment of trypanosomiasis. It has been shown to be effective in mice and polyneuritis, a serious side effect of nitrofurazone therapy, is less frequent with levofuraltadone. Nevertheless, levofuraltadone is a very toxic agent and it has never been commercially produced.
Status:
Investigational
Source:
INN:lunacalcipol [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Lunacalcipol (CTA-018 or MT-2832) is a vitamin D analog having a dual mechanism of action. It inhibits CYP24A1 and induced VDR expression. It was being developed for the treatment of clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease. Lunacalcipol development has been discontinued.
Class (Stereo):
CHEMICAL (RACEMIC)
Moxnidazole is an antiparasitic drug suitable for oral use against parasites in farm animals. administration of Moxnidazole in the drinking water gave good prophylaxis of dysentery in swine, histomoniasis in hens and turkeys, and trichomoniasis in pigeons. Isolated relapses were due to renfections and were successfully treated by another dose of the drug.
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Nifursol is an antibiotic of the nitrofuran class which inhibits the growth of the protozoa Histomonas meleagridis but is non-lethal. Although previously approved as a prophylactic feed additive for turkeys, the European Union has since banned Nifursol use in agricultural operations.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Bicyclomycin has been used to treat diarrhea in humans and bacterial diarrhea in calves and pigs and is marketed by Fujisawa (Osaka, Japan) under the trade name Bicozamycin. This drug is the selective inhibitor of rho, a member of the RecA-type ATPase class of enzymes that use nucleotide contacts to couple oligonucleotide translocation to ATP hydrolysis.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Plinabulin (formerly known as NPI-2358) is a potent microtubule-destabilizing agent that exerts its effect by binding to the colchicine-binding site of tubulin. Plinabulin projects its potent antitumor activity against a broad spectrum of tumor cell lines. This drug in combination with docetaxel is under development by BeyondSpring Pharmaceuticals in a worldwide Phase 3 clinical trial for non-small cell lung cancer. Pegfilgrastim is also in phase II clinical trial for the prevention of chemotherapy-induced neutropenia, where docetaxel, doxorubicin, and cyclophosphamide (TAC) were used as the chemotherapy. Plinabulin also possessed antitumor activity in animal models with multiple myeloma cancer cells, where the JNK protein appeared to be a primary target of plinabulin.
